文献速递免疫规划

单剂低剂量cGMP重组卡介苗诱导针对人呼吸道合胞病毒感染的保护性T细胞免疫并预防小鼠肺部病理

A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.
PubMed 文献 · Vaccine · 2017-01-05

本文描述一种表达人呼吸道合胞病毒(hRSV)核蛋白(N)的重组卡介苗(cGMP rBCG-N-hRSV)在小鼠中的保护性免疫效果。单剂该疫苗可保护小鼠抵抗1×10^7 PFU的hRSV A2临床株13018-8攻击,与未免疫感染对照相比,免疫小鼠体重丢失减少、气道中性粒细胞浸润减少、支气管肺泡灌洗液病毒载量降低。免疫后28天脾T细胞再刺激可激活分泌IFN-γ和IL-17的T细胞,提示诱导了混合型CD8+和CD4+ T细胞反应。

要点

  • 单剂cGMP rBCG-N-hRSV可保护小鼠抵抗1×10^7 PFU的hRSV A2临床株攻击。
  • 与未免疫感染对照相比,免疫小鼠体重丢失、气道中性粒细胞浸润和灌洗液病毒载量均降低。
  • 免疫后28天脾T细胞再刺激激活分泌IFN-γ和IL-17的T细胞,提示混合型CD8+和CD4+ T细胞反应。

核心结论

  • rBCG-N-hRSV是可用于人类预防hRSV所致疾病的有前景的候选疫苗。

研究设计与样本

  • 小鼠实验研究:以cGMP条件下配制的表达hRSV核蛋白(N)的重组卡介苗(rBCG-N-hRSV)单剂免疫小鼠,并以未免疫感染小鼠为对照,比较攻击后各项指标。

主要发现

  • 单剂cGMP rBCG-N-hRSV疫苗保留保护小鼠抵抗1×10^7 PFU的hRSV A2临床株13018-8攻击的能力。
  • 与未免疫感染对照相比,免疫小鼠体重丢失减少、气道内中性粒细胞浸润减少、支气管肺泡灌洗液病毒载量降低。
  • 免疫后28天脾T细胞体外再刺激激活分泌IFN-γ和IL-17的T细胞 repertoire,提示诱导了混合型CD8+和CD4+ T细胞反应,能够限制病毒播散并预防肺损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human respiratory syncytial virus (hRSV) is a major health burden worldwide, causing the majority of hospitalizations in children under two years old due to bronchiolitis and pneumonia. HRSV causes year-to-year outbreaks of disease, which also affects the elderly and immunocompromised adults. Furthermore, both hRSV morbidity and epidemics are explained by a consistently high rate of re-infections that take place throughout the patient life. Although significant efforts have been invested worldwide, currently there are no licensed vaccines to prevent hRSV infection. Here, we describe that a recombinant Bacillus Calmette-Guerin (BCG) vaccine expressing the nucleoprotein (N) of hRSV formulated under current good manufacture practices (cGMP rBCG-N-hRSV) confers protective immunity to the virus in mice. Our results show that a single dose of the GMP rBCG-N-hRSV vaccine retains its capacity to protect mice against a challenge with a disease-causing infection of 1×107 plaque-forming units (PFUs) of the hRSV A2 clinical strain 13018-8. Compared to unimmunized infected controls, vaccinated mice displayed reduced weight loss and less infiltration of neutrophils within the airways, as well as reduced viral loads in bronchoalveolar lavages, parameters that are characteristic of hRSV infection in mice. Also, ex vivo re-stimulation of splenic T cells at 28days post-immunization activated a repertoire of T cells secreting IFN-γ and IL-17, which further suggest that the rBCG-N-hRSV vaccine induced a mixed, CD8+ and CD4+ T cell response capable of both restraining viral spread and preventing damage of the lungs. All these features support the notion that rBCG-N-hRSV is a promising candidate vaccine to be used in humans to prevent the disease caused by hRSV in the susceptible population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Céspedes PF, Rey-Jurado E, Espinoza JA, et al. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice. Vaccine. 2017. PMID: 28065474. doi:10.1016/j.vaccine.2016.12.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。